Original Research
Accepted on 23 Feb 2026
Dose Optimization of Inhaled Tigecycline in Humans to Overcome Inherent Adverse Events and Maximize Bacterial Clearance Using a PBPK Modeling Approach
in Non-Tuberculous Mycobacteria
Frontiers in Tuberculosis
